High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

NCT03991130 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Melanoma Stage Iv
Renal Cell Carcinoma, Metastatic

Interventions

DRUG: IL-2 and Nivolumab

Sponsor

Gregory Daniels